-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 30, Qilu Pharmaceutical announced that the company 's market application for Disulumab injection has received notification of acceptance from NMPA
Qilu Pharmaceuticals announced that the company 's application for the marketing of Disulumab injection has received notification of acceptance from NMPA.
Bone is a common metastatic site for malignant tumors.
Disulumab injection is a new type of RANKL inhibitor originally developed by Amgen .
Disulumab injection is a new RANKL inhibitor originally developed by Amgen
In May 2019, Amgen's Disulumab injection was approved for use in giant cell tumors of bone in China, and was approved in November 2020 for bone-related events in patients with multiple myeloma and solid tumor bone metastases.
The first and only RANKL inhibitor approved for this indication in China
Although Amgen’s original Disulumab injection has a "first-mover" advantage, with Qilu Pharmaceutical's Disulumab biosimilar drug and other latecomers approved, the market space of the former will be squeezed
At present, 9 biosimilar drugs of Disumab in my country are in clinical trials.
Except Qilu Pharmaceuticals, the products of Corning Jerry, Shanghai Maiwei and Shandong Boan are progressing rapidly and have entered the phase 3 clinical phase.
